The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Investigators assessed the association between DFS and OS in patients with newly diagnosed, completely resected, intermediate-high or high-risk RCC post-nephrectomy.
A retrospective physician-administered chart review evaluated AEs and management strategies used in United States clinical practice among adult patients with aRCC.
No major difference in outcome was observed in a retrospective analysis of patients with mRCC and bone metastasis treated with IO with and without prior radiation.